Hale TL - Search Results

1

Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge.

Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR. Glenn GM, et al. Among authors: hale tl. J Immunol. 1998 Oct 1;161(7):3211-4. J Immunol. 1998. PMID: 9759833

2

Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection.

Mallett CP, Hale TL, Kaminski RW, Larsen T, Orr N, Cohen D, Lowell GH. Mallett CP, et al. Among authors: hale tl. Infect Immun. 1995 Jun;63(6):2382-6. doi: 10.1128/iai.63.6.2382-2386.1995. Infect Immun. 1995. PMID: 7768627 Free PMC article.

3

Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection.

van de Verg LL, Mallett CP, Collins HH, Larsen T, Hammack C, Hale TL. van de Verg LL, et al. Among authors: hale tl. Infect Immun. 1995 May;63(5):1947-54. doi: 10.1128/iai.63.5.1947-1954.1995. Infect Immun. 1995. PMID: 7729907 Free PMC article.

4

Protection against local Shigella sonnei infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine.

Levenson VJ, Mallett CP, Hale TL. Levenson VJ, et al. Among authors: hale tl. Infect Immun. 1995 Jul;63(7):2762-5. doi: 10.1128/iai.63.7.2762-2765.1995. Infect Immun. 1995. PMID: 7790095 Free PMC article.

5

Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model.

Mallett CP, VanDeVerg L, Collins HH, Hale TL. Mallett CP, et al. Among authors: hale tl. Vaccine. 1993;11(2):190-6. doi: 10.1016/0264-410x(93)90016-q. Vaccine. 1993. PMID: 8438617

6

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.

Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH. Fries LF, et al. Among authors: hale tl. Infect Immun. 2001 Jul;69(7):4545-53. doi: 10.1128/IAI.69.7.4545-4553.2001. Infect Immun. 2001. PMID: 11401998 Free PMC article. Clinical Trial.

7

Pathogenesis and immunology in shigellosis: applications for vaccine development.

Hale TL, Keren DF. Hale TL, et al. Curr Top Microbiol Immunol. 1992;180:117-37. doi: 10.1007/978-3-642-77238-2_6. Curr Top Microbiol Immunol. 1992. PMID: 1380415 Review. No abstract available.

8

Genotypic and phenotypic characterization of an aroD deletion-attenuated Escherichia coli K12-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen.

Newland JW, Hale TL, Formal SB. Newland JW, et al. Among authors: hale tl. Vaccine. 1992;10(11):766-76. doi: 10.1016/0264-410x(92)90512-i. Vaccine. 1992. PMID: 1441732

9

Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.

Barnoy S, Baqar S, Kaminski RW, Collins T, Nemelka K, Hale TL, Ranallo RT, Venkatesan MM. Barnoy S, et al. Among authors: hale tl. Vaccine. 2011 Aug 26;29(37):6371-8. doi: 10.1016/j.vaccine.2011.04.115. Epub 2011 May 17. Vaccine. 2011. PMID: 21596086

10

Hybrid vaccines using Escherichia coli as an antigen carrier.

Hale TL. Hale TL. Res Microbiol. 1990 Sep-Oct;141(7-8):913-9. doi: 10.1016/0923-2508(90)90130-i. Res Microbiol. 1990. PMID: 2101482 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters